Replies to post #7 on GPC Biotech AG (GPCB)

[mlkrborn]

FOOLMOTLEY's BRIAN WROTE ABOUT DNDN WHICH SURF BROUGHT TO OUR ATTENTION..
BRIAN SAID : "Those looking for an oncology-focused drugmaker with more impressive compounds in development should take a look at GPC Biotech (Nasdaq: GPCB) or Rule Breakers pick Exelixis (Nasdaq: EXEL) instead (OF DNDN --- MY ADDITION). It's time to go to CAPS and rate Dendreon underperform -- at least until the interim IMPACT data comes out."
very DRAMTIC dropp IN PPS over TIME .. IT LOOKS LIKE BOTTOM.. WHAT IS BOOK VALUE? ANY CASH? DEBT?
TIA